Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Oncorus Inc (NQ: ONCR )

N/A UNCHANGED
Last Price Updated: 11:52 AM EDT, Jun 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oncorus Inc

Oncorus Announces Workforce Reduction Plan
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
4 Stocks With Huge Cash Holdings at Silicon Valley Bank
How the recent failure of Silicon Valley Bank leaves several companies with significant deposits stuck in the bank. Will regulators step in and save the day? 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
From Oncorus, Inc.
Via GlobeNewswire
Oncorus to Participate in Upcoming Investor Conferences
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021 
From Oncorus, Inc.
Via GlobeNewswire
DPS Group Tapped by Oncorus to Design GMP Clinical Manufacturing Facility
Clinical stage biopharmaceutical company focused on viral immunotherapies building out state-of-the-art, 88,000 square foot facility in Massachusetts BOSTON, MA / ACCESSWIRE / September 22, 2021 / DPS... 
From DPS Group - Boston
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.